A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
The rationale for this study is to generate efficacy and safety data for the patient population with stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma following complete resection of their lesion(s).
The study will allow for direct comparison of the clinical benefit, as measured by recurrence-free survival and Overall survival, provided by ipilimumab and nivolumab
combination therapy versus ipilimumab and nivolumab monotherapy. It will provide clinical data allowing clinicians to select the appropriate treatment for each patient based on their individual risk-benefit ratio.